Skip to main content
    T

    Tvardi Therapeutics, Inc. (TVRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.08 (-6.78%)

    Market Cap: $15.74M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Tvardi Therapeutics, Inc. (TVRD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Tvardi Therapeutics (TVRD) to earn -$2.23 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.

    RatingAnalystsShare
    Strong Buy222.2%
    Buy555.6%
    Hold111.1%
    Sell00.0%
    Strong Sell111.1%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$2.23
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.18
    EPS consensus
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$2.23-$3.02 to -$1.609
    Dec 31, 2027-$2.18-$4.52 to -$0.519

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.43-$0.83 to -$0.1411

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202721

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.34.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.23-$2.23-$2.30-$2.35-$2.34N/A
    Fiscal year ending Dec 31, 2027-$2.18-$2.18-$2.24-$2.37-$2.73N/A

    Frequently Asked Questions About TVRD

    What is the TVRD stock forecast?

    Consensus analyst estimates put Tvardi Therapeutics's EPS at -$2.23 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.

    How do analysts rate TVRD stock?

    Of 9 analysts covering Tvardi Therapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TVRD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.23, with estimates from -$3.02 to -$1.60 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.18, with estimates from -$4.52 to -$0.51 from 9 analysts.

    How many analysts cover TVRD?

    9 analysts rate Tvardi Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.